September 2024 in “Journal of the American Academy of Dermatology” AH-001 could be a safer and more effective treatment for hair loss.
January 2026 in “Dermatologic Surgery” Injectable therapy, especially with dutasteride, may help with hair loss, but more research is needed.
January 2026 in “Journal of the American Academy of Dermatology”
February 2026 in “Biomedicines” Off-label treatments are heavily used for alopecia areata due to limited approved options.
February 2025 in “Prospects in Pharmaceutical Sciences” Clascoterone is a promising topical treatment for hair loss and acne with fewer side effects.
1 citations
,
October 2017 in “Food Additives & Contaminants: Part A” A new minoxidil-like substance, triaminodil, was found in an illegal hair growth supplement.
1 citations
,
February 2013 in “Steroids” Bone mineral and minocycline boost bone cell growth, aiding healing.
Dexmedetomidine-loaded microneedles effectively reduce pain without sedation.
3 citations
,
May 2024 in “International Journal of Dermatology”
September 2023 in “International Journal of Applied Pharmaceutics” The formulated gel is a promising treatment for alopecia areata.
1 citations
,
January 2018 in “Journal of cosmetology & trichology” Hair loss lotion with specific ingredients effectively improves hair growth and thickness safely.
Two nutritional supplements improved hair growth and reduced hair loss in women with hair loss conditions.
July 2024 in “Pharmaceutical Care España” Careful monitoring is needed when using oral minoxidil for hair loss due to potential side effects.
January 2025 in “Current Drug Delivery” TrichoSol™ and TrichoFoam™ are stable and effective for personalized alopecia treatments.
22 citations
,
November 2008 in “International Journal of Dermatology” A mix of 5-aminolevulinic acid and iron ion can speed up hair growth.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
50 citations
,
July 1981 in “Archives of Dermatology” DNCB helps regrow hair in alopecia areata patients, but safer alternatives are needed.
8 citations
,
April 2020 in “Journal of The American Academy of Dermatology” Bicalutamide may be a promising alternative treatment for female pattern hair loss.
17 citations
,
November 2009 in “Dermato-endocrinology” Medium-dose prednisolone pulse therapy is effective and safe for multifocal alopecia areata but not for more severe forms.
71 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.
June 2024 in “International Journal of Pharmaceutical Quality Assurance” The method accurately and quickly measures silodosin and dutasteride in mixtures.
February 2026 in “Expert Opinion on Pharmacotherapy” Low-dose oral and topical minoxidil are recommended for managing hair loss in transplant patients, with specific dosing and timing guidelines.
November 2023 in “Expert Opinion on Pharmacotherapy” Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.
April 2025 in “ACS Applied Nano Materials” A new treatment using dissolvable microneedles with nickel-copper and minoxidil improves hair growth and health in androgenetic alopecia.
January 2020 in “International Journal of Research in Pharmacy and Chemistry” A reliable method was created to measure dutasteride and related molecules in capsules.
September 2025 in “Journal of the American Academy of Dermatology” 26 citations
,
July 1992 in “International Journal of Dermatology” Oral cyclosporine A and prednisolone effectively improved alopecia universalis without side effects.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.